Cargando…

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma

BACKGROUND: Several clinical trials have shown that immune treatment focus on programmed death-1 and programmed death-ligand 1 (PD-L1) yields a good clinical efficacy in advanced non-small cell lung cancer (NSCLC). We investigated whether the PD-L1 expression was related to clinicopathologic and mol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Zhengbo, Yu, Xinmin, Cheng, Guoping, Zhang, Yiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919857/ https://www.ncbi.nlm.nih.gov/pubmed/27342566 http://dx.doi.org/10.1186/s12967-016-0943-4

Ejemplares similares

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma
por: Song, Zhengbo, et al.
Publicado: (2016)

The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma
por: Wu, Shafei, et al.
Publicado: (2017)

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2014)

Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients
por: Chen, Jun, et al.
Publicado: (2017)

Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma in situ and minimally invasive adenocarcinoma of lung
por: Yu, Renke, et al.
Publicado: (2017)

Clinicopathological characteristics correlated with programmed cell death-ligand 1 expression in advanced lung adenocarcinoma
por: Gao, Hengxing, et al.
Publicado: (2023)

PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2020)

Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma
por: Xu, Cheng, et al.
Publicado: (2018)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
por: Zhou, Wensheng, et al.
Publicado: (2022)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

HER2 mutations in Chinese patients with non-small cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2016)

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2019)

Significance of programmed death‐ligand 1 expression in resected lung cancer and its relationship with EGFR mutation
por: Osoegawa, Atsushi, et al.
Publicado: (2023)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Chemotherapy and prognosis in advanced thymic carcinoma patients
por: Song, Zhengbo, et al.
Publicado: (2015)

Rare frequency of gene variation and survival analysis in thymic epithelial tumors
por: Song, Zhengbo, et al.
Publicado: (2016)

Infiltration of tumor‐associated macrophages is involved in tumor programmed death‐ligand 1 expression in early lung adenocarcinoma
por: Shima, Toshiyuki, et al.
Publicado: (2020)

Prognostic significance of IMMT expression in surgically‐resected lung adenocarcinoma
por: Hiyoshi, Yasuhiro, et al.
Publicado: (2019)

Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer
por: Kim, Seok-Hyun, et al.
Publicado: (2019)

Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples
por: Muggilli, Michael, et al.
Publicado: (2021)

Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients
por: Wang, Shuo, et al.
Publicado: (2021)

Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

Preoperative CT Predicting Recurrence of Surgically Resected Adenocarcinoma of the Lung
por: Koo, Hyun Jung, et al.
Publicado: (2016)

Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression
por: Park, Ha-Young, et al.
Publicado: (2019)

Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma
por: Tessier-Cloutier, Basile, et al.
Publicado: (2017)

Five cases of BRAF V600E-mutant lung adenocarcinoma with high expression of programmed death ligand 1
por: Katano, Takuma, et al.
Publicado: (2020)

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
por: Kang, Minsu, et al.
Publicado: (2021)

Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients
por: Li, Kang, et al.
Publicado: (2022)

Cell‐blocks are suitable material for programmed cell death ligand‐1 immunohistochemistry: Comparison of cell‐blocks and matched surgical resection specimens in lung cancer
por: Pak, Min Gyoung, et al.
Publicado: (2019)

Programmed Death Ligand-1 Testing in Adenocarcinoma Lung: A Comparative Study of Cell Block versus Biopsy
por: Shukla, Saumya, et al.
Publicado: (2023)

Expression and Predictive Significance of FHL1 and SLIT3 in Surgically Resected Lung Adenocarcinoma
por: Song, Jinjing, et al.
Publicado: (2023)

A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas
por: Zhu, Ying, et al.
Publicado: (2020)

The expression of plakoglobin is a potential prognostic biomarker for patients with surgically resected lung adenocarcinoma
por: He, Xiaobo, et al.
Publicado: (2016)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase‐positive and surgically resected lung adenocarcinoma
por: Tao, Hong, et al.
Publicado: (2016)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)

The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures
por: Shi, Tao, et al.
Publicado: (2021)

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
por: Chen, Dan, et al.
Publicado: (2016)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q79rbo52t0c58amqv38q27a3ul